{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:53:43Z","timestamp":1773726823441,"version":"3.50.1"},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz. Dent. J."],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>Abstract This paper describes two cases in which the use of leucocyte-rich and platelet-rich fibrin (LPRF) combined with bone resection did not result in complete tissue response in the treatment of medication-related osteonecrosis of the jaw (MRONJ). It has been recently described in patients receiving subcutaneous administration of RANK-inhibitors, such as Denosumab, and anti-angiogenic drugs, such as Bevacizumab, as observed in our cases. Due to promising results in recent studies, more patients will receive these medications in order to avoid skeletal complications due to metastatic bone disease and, therefore, this scenario has a potential to become a comparable challenge to the bisphosphonate- induced jaw necrosis in the area of Oral and Maxillofacial Surgery. No convincing surgical technique has been described to overcome the non-healing mucosal lesions with exposed bone due to RANK-inhibitor therapy. Based on the findings in the literature and in both cases described herein can be concluded that the use of LPRF should be considered in the treatment of patients with DRONJ.<\/jats:p>","DOI":"10.1590\/0103-6440201600662","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T15:17:44Z","timestamp":1464016664000},"page":"353-358","source":"Crossref","is-referenced-by-count":16,"title":["Surgery Combined with LPRF in Denosumab Osteonecrosis of the Jaw: Case Report"],"prefix":"10.1590","volume":"27","author":[{"given":"Gustavo","family":"Maluf","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena Correia de","family":"Pinho","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra Ribeiro de Barros da","family":"Cunha","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo S\u00e9rgio da Silva","family":"Santos","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Rodrigues","family":"Fregnani","sequence":"additional","affiliation":[{"name":"Hospital S\u00edrio-Liban\u00eas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.oooo.2012.08.439","article-title":"The relationship of denosumab pharmacology and osteonecrosis of the jaws","volume":"114","author":"Malan J","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00784-014-1358-3","article-title":"Zoledronate but not denosumab suppresses macrophagic differentiation of THP-1 cells. An aetiologic model of bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"19","author":"Hoefert S","year":"2015","journal-title":"Clin Oral Investig"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","article-title":"Antiresorptives and osteonecrosis of the jaw","volume":"12","author":"Yamashita J","year":"2012","journal-title":"J Evid Based Dent Pract"},{"key":"ref4","series-title":"Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab)","author":"Oliveira CC","year":"2016"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update","volume":"72","author":"Ruggiero SL","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"ref6","series-title":"Medication Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab and New Agents","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-662-43733-9","volume-title":"Treatment of medication-related osteonecrosis of the jaw","author":"Otto S","year":"2015"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx RE","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero SL","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid IR","year":"2007","journal-title":"Bone"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias A","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood J","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi K","year":"2011","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double- blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry DH","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos MA","year":"2009","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti CI","year":"2009","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad F","year":"2012","journal-title":"Ann Oncol"},{"key":"ref17","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients","volume":"77","author":"Bonacina R","year":"2011","journal-title":"J Can Dent Assoc"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience","volume":"23","author":"Vandone AM","year":"2012","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bjoms.2011.08.004","article-title":"Treatment of bisphosphonate-related osteonecrosis of the jaws: Presentation of a protocol and an observational longitudinal study of an Italian series of cases","volume":"50","author":"Ferlito S","year":"2012","journal-title":"Br J Oral Maxillofac Surg"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hed.20864","article-title":"Treatment results of bisphosphonate-related osteonecrosis of the jaws","volume":"30","author":"Wutzl A","year":"2008","journal-title":"Head Neck"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jcms.2013.05.038","article-title":"Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection","volume":"41","author":"Otto S","year":"2013","journal-title":"J Craniomaxillofac Surg"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jcms.2012.10.014","article-title":"Denosumab osteonecrosis of the mandible: a new entity? A case report","volume":"41","author":"Pichardo SE","year":"2013","journal-title":"J Craniomaxillofac Surg"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","article-title":"Osteonecrosis of the jaw in a patient on Denosumab","volume":"68","author":"Aghaloo TL","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00198-013-2437-z","article-title":"Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab","volume":"25","author":"Neuprez A","year":"2014","journal-title":"Osteoporos Int"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2014.10.015","article-title":"Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature","volume":"51","author":"Del Fabbro M","year":"2015","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/ten.teb.2008.0062","article-title":"The biology of platelet-rich plasma and its application in oral surgery: literature review","volume":"14","author":"Nikolidakis D","year":"2015","journal-title":"Tissue Engineering: Part B"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.oraloncology.2011.12.004","article-title":"Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: A report of 32 cases","volume":"48","author":"Mozzati M Gallesio G","year":"2012","journal-title":"Oral Oncology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.joms.2013.07.027","article-title":"Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report","volume":"72","author":"Soydan SS Uckan S.","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tripleo.2005.07.010","article-title":"Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part III: Leucocyte activation: A new feature for platelet concentrate?","volume":"101","author":"Dohan DM","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.bjoms.2014.07.256","article-title":"Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study","volume":"52","author":"Kim JW","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","article-title":"Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)","volume":"43","author":"Ristow O","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze RM","year":"2014","journal-title":"Bone"}],"container-title":["Brazilian Dental Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bdj\/v27n3\/1806-4760-bdj-27-03-00353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:57:44Z","timestamp":1718585864000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0103-64402016000300353&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0103-64402016000300353"],"URL":"https:\/\/doi.org\/10.1590\/0103-6440201600662","relation":{},"ISSN":["0103-6440"],"issn-type":[{"value":"0103-6440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}